{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:33:38Z","timestamp":1767422018619,"version":"3.48.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"DOI":"10.7759\/cureus.100648","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:30:18Z","timestamp":1767421818000},"source":"Crossref","is-referenced-by-count":0,"title":["PIK3CA-Mutant Non-Small Cell Lung Cancer Refractory to Two Lines of Chemoimmunotherapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Takayuki","family":"Higashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazuki","family":"Takato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025, 75:10-45. 10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader N","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, et al.. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020, 383:640-9. 10.1056\/NEJMoa1916623","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-kinase, growth disorders, and cancer","volume":"379","author":"Goncalves MD","year":"2018","unstructured":"Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med. 2018, 379:2052-62. 10.1056\/NEJMra1704560","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and\u00a0vesicle trafficking","volume":"20","author":"Bilanges B","year":"2019","unstructured":"Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isoforms in cell signalling and\u00a0vesicle trafficking. Nat Rev Mol Cell Biol. 2019, 20:515-34. 10.1038\/s41580-019-0129-z","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1150799","article-title":"The structure of a human p110\u03b1\/p85\u03b1 complex elucidates the effects of oncogenic PI3K\u03b1 mutations","volume":"318","author":"Huang CH","year":"2007","unstructured":"Huang CH, Mandelker D, Schmidt-Kittler O, et al.. The structure of a human p110\u03b1\/p85\u03b1 complex elucidates the effects of oncogenic PI3K\u03b1 mutations. Science. 2007, 318:1744-8. 10.1126\/science.1150799","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Li S","year":"2014","unstructured":"Li S, Li L, Zhu Y, et al.. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer. 2014, 110:2812-20. 10.1038\/bjc.2014.210","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of phosphatidylinositol-3-kinase pathway alterations across 19\u202f784 diverse solid tumors","volume":"2","author":"Millis SZ","year":"2016","unstructured":"Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19\u202f784 diverse solid tumors. JAMA Oncol. 2016, 2:1565-73. 10.1001\/jamaoncol.2016.0891","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0692","article-title":"Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling","volume":"11","author":"Chaft JE","year":"2012","unstructured":"Chaft JE, Arcila ME, Paik PK, et al.. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther. 2012, 11:485-91. 10.1158\/1535-7163.MCT-11-0692","journal-title":"Mol Cancer Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3608241","article-title":"Clinical significance of PIK3CA gene in non-small-cell lung cancer: a systematic review and meta-analysis","volume":"2020","author":"Wang Y","year":"2020","unstructured":"Wang Y, Wang Y, Li J, Li J, Che G. Clinical significance of PIK3CA gene in non-small-cell lung cancer: a systematic review and meta-analysis. Biomed Res Int. 2020, 2020:3608241. 10.1155\/2020\/3608241","journal-title":"Biomed Res Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9 F","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, et al.. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019, 380:1929-40. 10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003402","article-title":"PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment","volume":"10","author":"Collins NB","year":"2022","unstructured":"Collins NB, Al Abosy R, Miller BC, et al.. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J Immunother Cancer. 2022, 10:10.1136\/jitc-2021-003402","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele F","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A, et al.. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020, 31:377-86. 10.1016\/j.annonc.2019.11.006","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0776-6","article-title":"PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer","volume":"9","author":"Wang Q","year":"2018","unstructured":"Wang Q, Shi YL, Zhou K, et al.. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018, 9:739. 10.1038\/s41419-018-0776-6","journal-title":"Cell Death Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S41643","article-title":"PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma","volume":"6","author":"Zhang L","year":"2013","unstructured":"Zhang L, Shi L, Zhao X, Wang Y, Yue W. PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther. 2013, 6:497-502. 10.2147\/OTT.S41643","journal-title":"Onco Targets Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088291","article-title":"PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup","volume":"9","author":"Wang L","year":"2014","unstructured":"Wang L, Hu H, Pan Y, et al.. PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup. PLoS ONE. 2014, 9:e88291. 10.1371\/journal.pone.0088291","journal-title":"PLoS ONE"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.02.023","article-title":"Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer","volume":"178","author":"Daher S","year":"2023","unstructured":"Daher S, Zer A, Tschernichovsky R, et al.. Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer. Lung Cancer. 2023, 178:229-36. 10.1016\/j.lungcan.2023.02.023","journal-title":"Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002917","article-title":"Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer","volume":"9","author":"Zhu S","year":"2021","unstructured":"Zhu S, Ma AH, Zhu Z, et al.. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002917","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03035-z","article-title":"Multi-node inhibition targeting mTORC1, mTORC2 and PI3K\u03b1 potently inhibits the PI3K\/AKT\/mTOR pathway in endometrial and breast cancer models","volume":"133","author":"Tyrakis PA","year":"2025","unstructured":"Tyrakis PA, Kampjut D, Steele GF, et al.. Multi-node inhibition targeting mTORC1, mTORC2 and PI3K\u03b1 potently inhibits the PI3K\/AKT\/mTOR pathway in endometrial and breast cancer models. Br J Cancer. 2025, 133:144-54. 10.1038\/s41416-025-03035-z","journal-title":"Br J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448459-pik3ca-mutant-non-small-cell-lung-cancer-refractory-to-two-lines-of-chemoimmunotherapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:30:18Z","timestamp":1767421818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448459-pik3ca-mutant-non-small-cell-lung-cancer-refractory-to-two-lines-of-chemoimmunotherapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.100648","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}